Taken together, c-Met is an important factor involved in the acquisition of resistance to targeted therapies, sustaining mesenchymal, undifferentiated phenotype, and increased renal carcinomas’ growth, progression and invasiveness. The gene discussed is MET; the disease is renal carcinoma.